Diisopropylethylamine → (2Z)-2-(3-butyl-5-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-1-(1,3-thiazol-4-yl)ethanone

HRID 448041

Reaction equation

HRID 448041 reaction equation
[S:1]1[CH:5]=[CH:4][N:3]=[C:2]1C(O)=O.CN([C:12]([O:16]N1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C.[I-].[CH2:43]([N+:47]1[N:51]=[C:50]([CH3:52])[S:49][C:48]=1[CH3:53])[CH2:44][CH2:45][CH3:46]>>[CH2:43]([N:47]1[N:51]=[C:50]([CH3:52])[S:49]/[C:48]/1=[CH:53]\[C:12]([C:4]1[N:3]=[CH:2][S:1][CH:5]=1)=[O:16])[CH2:44][CH2:45][CH3:46]

Participants

5

Reactant 4

HCID 81531DiisopropylethylamineHCID 27627331,3-Thiazole-2-carboxylic acidHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 691879173-Butyl-2,5-dimethyl-1,3,4-thiadiazol-3-ium iodide

Product 1

HCID 24955701(2Z)-2-(3-butyl-5-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-1-(1,3-thiazol-4-yl)ethanone

Procedure

In a 20 mL vial thiazole-2-carboxylic acid (0.9 mL of 0.2 M in DMA, 1.10 equiv) was added followed by the addition of HATU (77 mg in 0.7 mL of DMA, 0.2 mmol, 1.20 equiv.), DIEA (53 mg in 0.7 mL of DMA, 0.4 mmol, 2.40 equiv.), and finally 3-butyl-2,5-dimethyl-1,3,4-thiadiazol-3-ium iodide (50 mg in 0.7 mL of DMA, 0.17 mmol, 1 equiv.). The mixture was shaken overnight at room temperature and then concentrated in vacuo. The resulting residue was taken up in 1:1 DMSO/MeOH and purified by reverse phase HPLC using a method analogous to that described in Example 53 to provide the title compound. 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm 0.89 (t, 3 H) 1.25-1.38 (m, 2 H) 1.69-1.82 (m, 2 H) 2.46 (s, 3 H) 4.12-4.20 (m, 2 H) 6.81 (s, 1 H) 8.24 (s, 1 H) 9.15 (s, 1 H); MS (ESI) m/z 282 (M+H)+.

Workup

  1. concentrationconcentrated in vacuo
  2. custompurified by reverse phase HPLC

Sources & evidence

ORD record
ord-f5c76aa16f22436481cac3a2fa1d5e05
Source dataset
uspto-grants-2013_07
Patent number
US08481574B2

Linked notes

Loading…